Anterior Cruciate Ligament Study
Launched by I.R.C.C.S OSPEDALE GALEAZZI-SANT'AMBROGIO · Dec 22, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Anterior Cruciate Ligament (ACL) Study is looking at how often patients experience another ACL injury after having surgery to fix the ligament. The researchers are collecting information from patients treated between January 2020 and December 2030 to understand the factors that could lead to a re-injury. They will perform a test called the Lachmann test, which helps determine if the ACL has re-ruptured. Additionally, the study will explore things like age, gender, weight, and the types of sports people play to see if these factors influence the risk of injury.
To be eligible to participate in this study, you need to be between 18 and 65 years old, have had ACL reconstruction surgery at the hospital’s Casco unit during the specified time, and you must be able to provide consent if you’re undergoing surgery in the future. Participants will be asked to complete surveys about their quality of life and return to sports after their surgery. This research aims to help improve treatment and recovery for future ACL injuries, making it an important step for both current patients and future athletes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Males and females- attained skeletal maturity
- • 18-65 inclusive
- • Patients operated on anterior cruciate ligament reconstruction surgery at the Hospital's Casco unit from 2010 to 2030
- • Signature informed consent for patients who will be operated on in the prospective phase (from CE approval date to 2030)
- Exclusion Criteria:
- • failure to reach skeletal maturity
- • Concomitant ligamentous injuries (pcl, mcl, lcl)
- • Neuropsychiatric illness, developmental disorders
- • Pregnant women through self-declaration or breastfeeding
- • Minors
About I.R.C.C.S Ospedale Galeazzi Sant'ambrogio
The I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio is a leading clinical research institute and hospital in Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As a designated Institute of Hospitalization and Care of Scientific Relevance (I.R.C.C.S.), it focuses on translational research that bridges the gap between laboratory findings and clinical applications. The facility is equipped with state-of-the-art technology and a multidisciplinary team of experts, enabling it to conduct a wide range of clinical trials aimed at improving treatment outcomes across various medical fields. Its dedication to ethical practices and patient safety ensures that all research activities align with the highest international standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported